Trial · NCT03018704
Topiramate Treatment of Alcohol Use Disorders in African Americans
NCT03018704, Phase 4, Terminated, VA Office of Research and Development; results first posted 2023-03-23
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Topiramate Treatment of Alcohol Use Disorders in African Americans. Trials, record NCT03018704. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03018704
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Topiramate Treatment of Alcohol Use Disorders in African Americans
- NCT number
- NCT03018704
- Status
- Terminated
- Phases
- Phase 4
- Enrollment
- 79 participants, actual
- Lead sponsor
- VA Office of Research and Development
- Conditions
- Alcohol Use Disorder
- Interventions
- Topiramate, placebo
- First posted
- 2017-01-12
- Last updated
- 2023-03-23
- Results first posted
- 2023-03-23
- Limitations and caveats
- The study was stopped by the funding agency due to difficulty recruiting during COVID pandemic
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent Days of Heavy Drinking | 12 weeks | Drinking was recorded using the timeline follow back methodology which is an interview based method to record drinking on each day during the trial. The summary measure (% days heavy drinking) counts the number of days of heavy drinking (\>4drinks per day) divided by the number of observation days to report the percent of observation days for which there is heavy drinking. For the the outcome measure the observation period is the last 42 days of the trial. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percent Days of Heavy Drinking | 12 weeks | percentage of days of heavy drinking | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Days of Heavy Drinking | Placebo | 26.7 | Standard Deviation 24.9 | percentage of days of heavy drinking | |
| Percent Days of Heavy Drinking | Topiramate | 14.8 | Standard Deviation 14.6 | percentage of days of heavy drinking |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo | 19 | |
| Overall Study | STARTED | Topiramate | 18 | |
| Overall Study | COMPLETED | Placebo | 18 | |
| Overall Study | COMPLETED | Topiramate | 17 | |
| Overall Study | NOT COMPLETED | Placebo | 1 | |
| Overall Study | NOT COMPLETED | Topiramate | 1 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo | 0 | 19 |
| Total, all-cause mortality | Topiramate | 0 | 18 |
| Total, other adverse events | Placebo | 0 | 19 |
| Total, other adverse events | Topiramate | 0 | 18 |
| Total, serious adverse events | Placebo | 0 | 19 |
| Total, serious adverse events | Topiramate | 0 | 18 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Topiramate vs Placebo: deaths from any cause | Trial comparisons |
| Topiramate vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03018704
GET https://conductscience.org/api/trials/v1/NCT03018704/registered